Lean Hogs (LH)

Dernières nouvelles pour Labcorp Hldgs (NYSE:LH) Stock

Labcorp Holdings

Labcorp Hldgs

Laboratory Corp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Truist Securities analyst David Macdonald maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $290 to $310.

News

Price Target

Analyst Ratings

Laboratory Corporation Of America Holdings

Truist Securities Maintains Buy on Labcorp Hldgs, Raises Price Target to $310

UBS analyst Kevin Caliendo maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $282 to $305.

UBS Maintains Buy on Labcorp Hldgs, Raises Price Target to $305

Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $285 to $300.

Evercore ISI Group Maintains Outperform on Labcorp Hldgs, Raises Price Target to $300

Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) on Thursday reported stronger-than-expected results <a href="https://www.benzinga.com/quote/lh/earnings">for the second quarter</a>.
The company posted second-quarter 2025 adjusted earnings per share of $4.35, up from $3.94 a year ago, beating the consensus of $4.17. Sales increased 9.5% year-over-year to $3.53 billion, beating the consensus of $3.485 billion.
LabCorp raised its fiscal year 2025 adjusted earnings guidance from $15.70-$16.40 to $16.05-$16.50, compared to the consensus of $16.09. The company also raised 2025 sales guidance from $13.978 billion-$14.148 billion to $14.08 billion-$14.23 billion compared to the consensus of $13.897 billion. LabCorp forecasts 2025 sales growth of 7.5%-8.6% compared to prior guidance of 6.7%-8%.
&#8220;Labcorp had a very strong second quarter, delivering double-digit topline growth, while expanding margins across both segments,&#8221; said Adam Schechter, chairman and CEO of Labcorp. &#8220;We brought innovative tests to market, and applied our leadership in science and technology to drive growth, enhance the customer experience and improve our operations.  We remain committed to delivering sustained value to our customers, employees and shareholders as we execute on our long-term strategy. Based upon our performance in the first half and our momentum going into the second half of the year, we&#8217;re raising our guidance.&#8221;
Labcorp shares gained 6.9% to trade at $267.69 on Friday.
These analysts made changes to their price targets on Labcorp following earnings announcement.
<ul class="wp-block-list">
<li>Baird analyst Eric Coldwell maintained Labcorp with an Outperform rating and raised the price target from $290 to $302.</li>
<li>Morgan Stanley analyst Ricky Goldwasser maintained the stock with an Overweight rating and raised the price target from $283 to $306.</li>
</ul>
Considering buying LH stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25094413/image-406-1024x586.png" alt="" class="wp-image-1000859" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25094413/image-406-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25094413/image-406-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25094413/image-406-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25094413/image-406.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter"> Top 2 Tech Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

These Analysts Boost Their Forecasts On Labcorp Following Better-Than-Expected Q2 Earnings

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Deutsche Bank raised Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) price target from $97 to $105. Deutsche Bank analyst Brian Bedell maintained a Buy rating. Nasdaq shares closed at $93.50 on Thursday. See how other <a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings">analysts view this stock</a>.</li>
<li>Keybanc increased the price target for United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from $865 to $960. Keybanc analyst Ken Newman maintained an Overweight rating. United Rentals shares closed at $875.25 on Thursday. <a href="https://www.benzinga.com/quote/URI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan slashed Teck Resources Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) price target from $46 to $41. JP Morgan analyst Bill Peterson downgraded the stock from Overweight to Neutral. Teck Resources shares closed at $35.12 on Thursday. <a href="https://www.benzinga.com/quote/TECK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies boosted the price target for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from $250 to $285. Jefferies analyst Stephanie Moore upgraded the stock from Hold to Buy. Union Pacific shares closed at $220.52 on Thursday. <a href="https://www.benzinga.com/quote/UN[/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Sidoti &amp; Co. increased the price target for Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) from $135 to $150. Sidoti &amp; Co. analyst Anja Soderstrom upgraded the stock from Neutral to Buy. Plexus shares closed at $118.29 on Thursday. <a href="https://www.benzinga.com/quote/PLXS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) price target from $55 to $60. Baird analyst Daniel Moore maintained an Outperform rating. Knight-Swift Transportation shares settled at $45.55 on Thursday. <a href="https://www.benzinga.com/quote/KNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) price target from $625 to $650. Rosenblatt analyst Blair Abernethy maintained a Buy rating. Synopsys shares closed at $609.68 on Thursday. <a href="https://www.benzinga.com/quote/SNPS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $80 to $75. Stifel analyst Jonathan Block downgraded the stock from Buy to Hold. Henry Schein shares closed at $72.62 on Thursday.  <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for IMAX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) from $35 to $37. Rosenblatt analyst Steve Frankel maintained a Buy rating. IMAX shares settled at $28.29 on Thursday. <a href="https://www.benzinga.com/quote/IMAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) price target from $283 to $306. Morgan Stanley analyst Ricky Goldwasser maintained an Overweight rating. Labcorp shares closed at $267.69 on Thursday. <a href="https://www.benzinga.com/quote/lh/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NDAQ stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25090118/image-401-1024x582.png" alt="" class="wp-image-1000765" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25090118/image-401-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25090118/image-401-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25090118/image-401-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25090118/image-401.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo via Shutterstock

HSIC

IMAX

NDAQ

PLXS

SNPS

TECK

Nasdaq To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Friday

Ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $282.0, a high estimate of $306.00, and a low estimate of $250.00. This current average has increased by 5.86% from the previous average price target of $266.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1753448441_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Labcorp Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$306.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$302.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$282.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$253.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Labcorp Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Labcorp Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Delving into Labcorp Hldgs's Background</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Breaking Down Labcorp Hldgs's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Labcorp Hldgs displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.36%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Labcorp Hldgs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.6% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Labcorp Hldgs's ROA excels beyond industry benchmarks, reaching 1.18%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Labcorp Hldgs

Morgan Stanley analyst Ricky Goldwasser maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Overweight and raises the price target from $283 to $306.

Morgan Stanley Maintains Overweight on Labcorp Hldgs, Raises Price Target to $306

Baird analyst Eric Coldwell maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $290 to $302.

Baird Maintains Outperform on Labcorp Hldgs, Raises Price Target to $302

Laboratory Corp&nbsp;(NYSE: LH) on Thursday reported second-quarter 2025 adjusted earnings per share of $4.35, up from $3.94 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $4.17</a>.
Sales increased 9.5% year-over-year to $3.53 billion, beating the consensus of $3.485 billion.
The increase was due to organic revenue growth of 5.4%, acquisitions, net of divestitures, of 3.5%, and foreign <a href="https://www.benzinga.com/pressreleases/25/07/n46596730/labcorp-announces-2025-second-quarter-results" target="_blank" rel="noreferrer noopener">currency translation of 0.6%</a>.
Adjusted operating income for the quarter was $531.6 million, or 15.1% of revenue. 
Labcorp delivered double-digit topline growth, while expanding margins across both segments, said Adam Schechter, chairman and CEO of Labcorp. &#8220;Based upon our performance in the first half and our momentum going into the second half of the year, we&#8217;re raising our guidance,&#8221; he added.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46102684/could-personalized-medicine-be-your-portfolios-next-big-winner-find-out" target="_blank" rel="noreferrer noopener">Could Personalized Medicine Be Your Portfolio&#8217;s Next Big Winner? Find Out</a>
In the second quarter, Labcorp:
<ul class="wp-block-list">
<li>Announced an agreement to acquire select assets of Incyte Diagnostics&#8217; clinical and anatomic pathology testing businesses in the Pacific Northwest.</li>
<li>Continued to progress the acquisition of select oncology and clinical testing assets from BioReference Health.</li>
<li>Labcorp acquired select assets of the outreach business from Community Health Systems across 13 states for <a href="https://www.benzinga.com/pressreleases/25/07/b46558914/community-health-systems-announces-definitive-agreement-to-sell-select-outreach-laboratory-assets-" target="_blank" rel="noreferrer noopener">$195 million in cash</a>.</li>
</ul>
Guidance: LabCorp raised its fiscal year 2025 adjusted earnings guidance&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45061959/labcorp-announces-2025-first-quarter-results" rel="noreferrer noopener">from&nbsp;$15.70-$16.40</a>&nbsp;to&nbsp;$16.05-$16.50, compared to the consensus of&nbsp;$16.09.
The company also raised 2025 sales&nbsp;guidance&nbsp;from&nbsp;$13.978 billion-$14.148 billion&nbsp;to&nbsp;$14.08 billion-$14.23 billion&nbsp;compared to the consensus of $13.897 billion.
LabCorp forecasts 2025 sales growth of 7.5%-8.6% compared to prior guidance of 6.7%-8%.
The guidance includes 2025 Diagnostics Laboratories sales growth of 7%-8% (compared to prior guidance of 6.5%-7.7%) and Biopharma Laboratory Services sales growth of 6.1%-7.5% (compared to prior guidance of 3.0%-5.0%).
William Blair writes, &#8220;In terms of the quarter, organic growth trends in Labcorp&#8217;s diagnostics segment improved quarter-over-quarter, though admittedly this growth was a tad below consensus expectations. We are not overly concerned with the slight miss here given what we still believe are favorable tailwinds impacting reference labs, including heightened
utilization trends, stable unit pricing, mix benefits, share wins, and a compelling M&amp;A pipeline.&#8221;
Price Action:&nbsp;Laboratory stock is up 11.3% at $278.91 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46597046/sonys-chipset-unit-up-for-sale-to-fuel-entertainment-push" target="_blank" rel="noreferrer noopener">Sony&#8217;s Chipset Unit Up For Sale To Fuel Entertainment Push</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Guidance

Health Care

Movers

General

Why Is Testing Giant Labcorp Stock Surging On Thursday?

WIIM

Labcorp shares are trading higher after raising FY25 EPS and sales guidance above estimates.

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Thursday.
Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) rose sharply on Thursday following better-than-expected <a href="https://www.benzinga.com/quote/RPM/earnings">quarterly EPS and sales.</a>
RPM International reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.59 per share. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.02 billion.
RPM International shares jumped 10.2% to $124.46 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares jumped 23.7% to $281.65 after raising FY25 EPS and sales guidance above estimates.</li>
<li>ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) gained 19% to $199.68 after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 18.8% to $31.97 after the company announced its fuel cell technology will be deployed at select Oracle Cloud Infrastructure data centers in the US.</li>
<li>MaxLinear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) rose 16.6% to $17.87 after the company reported better-than-expected second-quarter sales results and issued third-quarter sales guidance with its midpoint above estimates.</li>
<li>ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) gained 16.1% to $58.08 after the company reported better-than-expected quarterly financial results.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) rose 15.3% to $11.81.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) gained 14% to $4.5250.</li>
<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) rose 14% to $1.6850.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 12.2% to $8.56.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 11.4% to $279.00 as the company posted upbeat quarterly results and raised its FY25 forecast.</li>
<li>TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) gained 10.4% to $37.09 following upbeat quarterly results.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) gained 8.4% to $33.91 after the company reported better-than-expected Q2 sales results.</li>
<li>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) rose 8.2% to $181.78.</li>
<li>FirstService Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NYSE">FSV</a>) gained 8% to $193.42 following upbeat quarterly results.</li>
<li>Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) gained 6.7% to $94.22 after the company reported better-than-expected second-quarter financial results.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) rose 6.7% to $249.90 after the company reported better-than-expected second-quarter earnings.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Photo via Shutterstock

Intraday Update

ARAI

ASGN

ICLR

MVIS

SLDP

TMUS

RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On Thursday

Guidance for 2025
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">(Dollars in billions, except per share data)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Previous</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Labcorp Enterprise (1)(2)</td>
<td colspan="1" rowspan="1">$13.01</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.7&nbsp;%</td>
<td colspan="1" rowspan="1">8.0&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7.5&nbsp;%</td>
<td colspan="1" rowspan="1">8.6&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diagnostics Laboratories(3)</td>
<td colspan="1" rowspan="1">$10.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.5&nbsp;%</td>
<td colspan="1" rowspan="1">7.7&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7.0&nbsp;%</td>
<td colspan="1" rowspan="1">8.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biopharma Laboratory Services (4)</td>
<td colspan="1" rowspan="1">$2.92</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.0&nbsp;%</td>
<td colspan="1" rowspan="1">5.0&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.1&nbsp;%</td>
<td colspan="1" rowspan="1">7.5&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$14.57</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$15.70</td>
<td colspan="1" rowspan="1">$16.40</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$16.05</td>
<td colspan="1" rowspan="1">$16.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1">$1.25</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.13</td>
<td colspan="1" rowspan="1">$1.28</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="8" rowspan="1">(1) 2025 Guidance includes an impact from foreign currency translation of 0.5%.</td>
</tr>
<tr>
<td colspan="8" rowspan="1">(2) Enterprise level revenue is presented net of intersegment transaction eliminations.</td>
</tr>
<tr>
<td colspan="8" rowspan="1">(3) 2025 Guidance includes an impact from foreign currency translation of (0.1%).</td>
</tr>
<tr>
<td colspan="5" rowspan="1">(4) 2025 Guidance includes an impact from foreign currency translation of 2.5%.</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Labcorp Hldgs Raises FY2025 Adj EPS Guidance from $15.70-$16.40 to $16.05-$16.50 vs $16.09 Est; Raises FY2025 Sales Guidance from $13.978B-$14.148B to $14.080B-$14.230B vs $13.897B Est

Laboratory Corp Q2 2025 Adj. EPS $4.35 Beats $4.17 Estimate, Sales $3.530B Beat $3.485B Estimate

ALEX

ALLE

AMAL

AMBP

AMSF

ASPS

BELFA

BELFB

BHLB

BWMX

CIVB

COKE

COLB

COUR

CUBI

DAIO

DCOM

DECK

DGICA

DGICB

ENSG

ENVA

FBIZ

FCFS

FFBC

FFIC

FINW

FISI

FLEX

FRST

GBCI

GLPI

HFWA

IBCP

INTC

IRDM

ITGR

JAKK

KNSL

LADR

LARK

LBRT

MBLY

MGRC

MOFG

MSBI

MTLS

MYFW

Earnings Scheduled For July 24, 2025

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is preparing to release its quarterly earnings on Thursday, 2025-07-24. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Laboratory Corp to report an earnings per share (EPS) of $4.16.
Investors in Laboratory Corp are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.33, leading to a 0.25% increase in the share price the following trading session.
Here's a look at Laboratory Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>4.17</td>
<td>3.39</td>
<td>3.49</td>
<td>3.78</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.84</td>
<td>3.45</td>
<td>3.50</td>
<td>3.94</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753279350_0.png" alt="eps graph" />
<h3>Performance of Laboratory Corp Shares</h3>
Shares of Laboratory Corp were trading at $252.07 as of July 22. Over the last 52-week period, shares are up 21.69%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Laboratory Corp</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Laboratory Corp.
Analysts have provided Laboratory Corp with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $276.5, suggesting a potential 9.69% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Quest Diagnostics, Hims &amp; Hers Health and Chemed, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Quest Diagnostics, with an average 1-year price target of $188.33, suggesting a potential 25.29% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Hims &amp; Hers Health, with an average 1-year price target of $40.4, suggesting a potential 83.97% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $654.67, suggesting a potential 159.72% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Quest Diagnostics, Hims &amp; Hers Health and Chemed, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labcorp Hldgs</td>
<td>Neutral</td>
<td>5.30%</td>
<td>$948M</td>
<td>2.60%</td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td>Neutral</td>
<td>12.09%</td>
<td>$863M</td>
<td>3.20%</td>
</tr>
<tr>
<td>Hims &amp; Hers Health</td>
<td>Neutral</td>
<td>110.67%</td>
<td>$430.69M</td>
<td>9.65%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>9.79%</td>
<td>$216.41M</td>
<td>6.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Laboratory Corp ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth and Return on Equity.
<h3>Delving into Laboratory Corp's Background</h3>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Unraveling the Financial Story of Laboratory Corp</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Laboratory Corp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.3% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.36%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.6%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Laboratory Corp's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.18% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Laboratory Corp's debt-to-equity ratio surpasses industry norms, standing at 0.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/LH/earnings">To track all earnings releases for Laboratory Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Laboratory Corp's Earnings Potential

Community Health Systems, Inc. (Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has entered into a definitive agreement with Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), pursuant to which Labcorp will acquire select assets and assume certain leases of the ambulatory outreach laboratory services of CHS health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, for $195 million cash.
When the transaction is complete, CHS patients and providers will benefit from broader access to Labcorp's comprehensive testing and laboratory services, including its specialty testing menu, robust data analytics and digital tools. CHS health systems will continue to operate their inpatient and emergency department laboratories and will continue to provide laboratory services for hospital-based services, such as imaging and pre-admission testing.
"We are excited about this transaction with Labcorp, which allows us to focus on our core services and improve the overall patient experience, aligning with our unwavering commitment to providing high-quality, accessible healthcare to our communities," said Kevin Stockton, Executive Vice President, Operations and Development for CHS. "Labcorp's scale and investment in technology supports its ability to efficiently deliver outreach laboratory services to patients and healthcare consumers."
"Labcorp and Community Health Systems share a deep commitment to improving the health and lives of the communities we serve, and our goal with this agreement is to enhance the patient and provider experience with increased access to high-quality laboratory services," added Mark Schroeder, EVP and President, Diagnostics Laboratories and Chief Operations Officer, Labcorp. "This acquisition will allow us to leverage the strengths of both our organizations to positively impact healthcare for communities across the U.S."
The organizations are committed to working together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clinicians and clients, while providing direct access to the additional capabilities of Labcorp.
This relationship is similar to other strategic relationships that Labcorp has with a range of local and regional health systems that have enhanced services for patients and providers.
The transaction is subject to customary closing conditions and applicable regulatory approvals. The companies anticipate closing the transaction in the fourth quarter of 2025. Until that time, there will be no changes in operations or services.

Community Health Systems' Subsidiary, CHS/Community Health Systems, And Labcorp Enter Into A Definitive Agreement; Labcorp To Acquire Select Assets And Assume Certain Leases Of The Ambulatory Outreach Laboratory Services Of CHS Health Systems In 13 States For $195M In Cash

UBS analyst Kevin Caliendo maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $284 to $282.

UBS Maintains Buy on Labcorp Hldgs, Lowers Price Target to $282

Seasonality suggests that markets will fade ahead through August and September before rising again.
Knowing this, it&#8217;s an excellent time to start looking for bearish trades. One company in particular is a very promising target.
<h2 class="wp-block-heading">Live Sunday: Matt Maley's Volatility Trading Plan for Earnings, Tariffs &amp; the Fed</h2>
Three big catalysts are gearing up to hit the markets at month's end.&nbsp;Matt Maley is going live&nbsp;this Sunday at 1 PM ET&nbsp;to reveal how he's trading short-term setups across financials, tech, defense, and more. If you're watching earnings, tariff drama, or Fed risk—this is your moment to act. See Matt's full strategy&nbsp;<a href="https://events2.benzinga.com/matt-maley-webinar-sun-july20-2025-registration/?utm_campaign=webinar072025&amp;utm_adType=sponsorad&amp;utm_ad=RD071825" target="_blank" rel="noreferrer noopener">HERE</a>
Here&#8217;s my favorite options trade for this week.
Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) has come down off its highs for the year and looks set to keep coasting down as the late summer doldrums take hold. Statistically speaking, this stock has performed poorly through August and September. Its relative resistance zone sits right around $265, while support sits near $230. 
That makes it a great target for a long put spread. This type of trade is created by buying a long put and selling a short put further out of the money. The short put will finance the long put. As prices fall, the long put rises quickly in price, and as the short strike is further away, it rises more slowly, creating a profit cushion for the trader. 
Here&#8217;s our trade:
<ul class="wp-block-list">
<li>Buy to open (1) 19 Sept $240 put</li>
<li>Sell to open (1) 19 Sept $230 put</li>
</ul>
This long put spread currently carries a debit of $3.40. That&#8217;s the trade&#8217;s total cost and total risk ($340). One can calculate the breakeven price by subtracting the cost of the spread from the strike of $240, so $240 &#8211; $3.40 = $236.60.
The max profit equals the difference between the two strikes, less the cost of the spread, so $240 &#8211; $230 &#8211; $3.40 = $6.30 (less commissions).
The possible ways to leave the trade include:
<ul class="wp-block-list">
<li>Hold the position until around the third week of September. Close the trade in the middle of the week to trade this from a seasonality perspective.&nbsp;</li>
<li>Close the trade at a predetermined profit event. This might be 25%, 50%, or more &#8211; this is a personal choice. I would prefer to look at price action behavior near $233.&nbsp;</li>
<li>Set an alert for the stock price of $255; the breach of this level suggests that closing the trade is required.&nbsp;</li>
<li>Alternatively, set an alert for a spread price of $2.00 – the loss of the price of the spread suggests it&#8217;s time to close the trade.</li>
</ul>
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Image: Shutterstock
<ol class="wp-block-list"></ol>

Opinion

My Favorite Options Trade For This Week

Labcorp Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) short percent of float has risen 3.37% since its last report. The company recently reported that it has 3.56 million shares sold short, which is 5.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Labcorp Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752764441_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Labcorp Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Labcorp Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Labcorp Hldgs's peer group average for short interest as a percentage of float is 10.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Labcorp Hldgs?

Throughout the last three months, 8 analysts have evaluated Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $275.5, a high estimate of $290.00, and a low estimate of $250.00. Surpassing the previous average price target of $261.50, the current average has increased by 5.35%.
<img src="https://www.benzinga.com/files/images/story/2025/1752094847_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Labcorp Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$274.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Labcorp Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Labcorp Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Hldgs</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Milestones: Labcorp Hldgs's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Labcorp Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.3% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin excels beyond industry benchmarks, reaching 6.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Labcorp Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.6%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Labcorp Hldgs's ROA excels beyond industry benchmarks, reaching 1.18%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 0.78. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Labcorp Hldgs: Insights From 8 Analyst Reviews

Press Releases

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Labcorp Launches Labcorp Whole Health Solutions to Support Holistic Care

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

Management

Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

Dividends

Labcorp Declares Quarterly Dividend

Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

Labcorp Announces 2025 Second Quarter Results

POAI

PRVA

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Hldgs

Actualités

Dernières nouvelles pour Labcorp Hldgs (NYSE:LH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL